JP2003512421A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2003512421A5 JP2003512421A5 JP2001532749A JP2001532749A JP2003512421A5 JP 2003512421 A5 JP2003512421 A5 JP 2003512421A5 JP 2001532749 A JP2001532749 A JP 2001532749A JP 2001532749 A JP2001532749 A JP 2001532749A JP 2003512421 A5 JP2003512421 A5 JP 2003512421A5
- Authority
- JP
- Japan
- Prior art keywords
- bms
- pyrimidin
- hydroxymethyl
- cis
- amino
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- JTEGQNOMFQHVDC-NKWVEPMBSA-N lamivudine Chemical compound O=C1N=C(N)C=CN1[C@H]1O[C@@H](CO)SC1 JTEGQNOMFQHVDC-NKWVEPMBSA-N 0.000 description 6
- 239000004480 active ingredient Substances 0.000 description 3
- 229940000425 combination drug Drugs 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 229960001627 lamivudine Drugs 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- -1 2-hydroxymethyl-1,3-oxathiolane-5-yl Chemical group 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- QDGZDCVAUDNJFG-FXQIFTODSA-N entecavir (anhydrous) Chemical compound C1=2NC(N)=NC(=O)C=2N=CN1[C@H]1C[C@H](O)[C@@H](CO)C1=C QDGZDCVAUDNJFG-FXQIFTODSA-N 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- VTGOHKSTWXHQJK-UHFFFAOYSA-N pyrimidin-2-ol Chemical compound OC1=NC=CC=N1 VTGOHKSTWXHQJK-UHFFFAOYSA-N 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US09/429,863 US6432966B2 (en) | 1999-10-29 | 1999-10-29 | Antiviral combinations |
| US09/429,863 | 1999-10-29 | ||
| PCT/GB2000/004137 WO2001030329A2 (en) | 1999-10-29 | 2000-10-27 | Combinations of lamivudine and entecavir for treatment of hepatitis b virus infuction |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2003512421A JP2003512421A (ja) | 2003-04-02 |
| JP2003512421A5 true JP2003512421A5 (enExample) | 2007-12-20 |
Family
ID=23705033
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2001532749A Pending JP2003512421A (ja) | 1999-10-29 | 2000-10-27 | 抗ウィルス複合薬 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US6432966B2 (enExample) |
| EP (1) | EP1225904B1 (enExample) |
| JP (1) | JP2003512421A (enExample) |
| AR (1) | AR026255A1 (enExample) |
| AT (1) | ATE273012T1 (enExample) |
| AU (1) | AU1042701A (enExample) |
| DE (1) | DE60012961T2 (enExample) |
| ES (1) | ES2225245T3 (enExample) |
| TW (1) | TWI282735B (enExample) |
| WO (1) | WO2001030329A2 (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE312613T1 (de) † | 2000-02-29 | 2005-12-15 | Bristol Myers Squibb Co | Niedrig dosierte entecavir formulierung und deren verwendung |
| US20030229058A1 (en) * | 2001-11-13 | 2003-12-11 | Moran Edmund J. | Aryl aniline beta2 adrenergic receptor agonists |
| US8168568B1 (en) * | 2003-03-10 | 2012-05-01 | The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services | Combinatorial therapy for protein signaling diseases |
| TWI526219B (zh) | 2008-06-19 | 2016-03-21 | 腫瘤療法 科學股份有限公司 | Ｃｄｃａ１抗原決定位胜肽及含此胜肽的疫苗 |
| CN102552210B (zh) * | 2012-01-10 | 2013-12-11 | 四川海思科制药有限公司 | 一种恩替卡韦胶囊组合物及其制备方法 |
| US20180110796A1 (en) * | 2015-04-07 | 2018-04-26 | Spring Bank Pharmaceuticals, Inc. | Compositions and methods for the treatment of hbv infection |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE9800452D0 (sv) * | 1998-02-13 | 1998-02-13 | Medivir Ab | Antivirals |
| US5047407A (en) * | 1989-02-08 | 1991-09-10 | Iaf Biochem International, Inc. | 2-substituted-5-substituted-1,3-oxathiolanes with antiviral properties |
| GB9009861D0 (en) | 1990-05-02 | 1990-06-27 | Glaxo Group Ltd | Chemical compounds |
| US5206244A (en) | 1990-10-18 | 1993-04-27 | E. R. Squibb & Sons, Inc. | Hydroxymethyl (methylenecyclopentyl) purines and pyrimidines |
| IL100502A (en) | 1991-01-03 | 1995-12-08 | Iaf Biochem Int | PHARMACEUTICAL PREPARATIONS CONTAINING CIS-4-AMINO-1-) 2-HYDROXIMETHIL-1,3-OXETYOLEN-5-IL (- |
| ATE131730T1 (de) | 1991-05-16 | 1996-01-15 | Glaxo Group Ltd | Nukleosidanalogen enthaltende antiviren- zubereitungen |
| IL113432A (en) | 1994-04-23 | 2000-11-21 | Glaxo Group Ltd | Process for the diastereoselective synthesis of nucleoside analogues |
| MY115461A (en) | 1995-03-30 | 2003-06-30 | Wellcome Found | Synergistic combinations of zidovudine, 1592u89 and 3tc |
| TW536403B (en) * | 1997-03-24 | 2003-06-11 | Glaxo Group Ltd | An ethanol and ethylenediaminetetraacetic acid free pharmaceutical composition comprising lamivudine and exhibiting antimicrobial preservative efficacy |
| BR9808564A (pt) * | 1997-04-15 | 2000-05-23 | Advanced Viral Res Corp | Método de tratar um paciente tendo infecções por hiv |
| WO1999015175A1 (en) * | 1997-09-25 | 1999-04-01 | Cornell Research Foundation, Inc. | Method for inhibiting development of liver cancer and increasing survival in chronic hepadnavirus infection |
-
1999
- 1999-10-29 US US09/429,863 patent/US6432966B2/en not_active Expired - Lifetime
-
2000
- 2000-10-26 AR ARP000105645A patent/AR026255A1/es not_active Application Discontinuation
- 2000-10-27 TW TW089122670A patent/TWI282735B/zh not_active IP Right Cessation
- 2000-10-27 EP EP00971593A patent/EP1225904B1/en not_active Expired - Lifetime
- 2000-10-27 DE DE60012961T patent/DE60012961T2/de not_active Expired - Lifetime
- 2000-10-27 WO PCT/GB2000/004137 patent/WO2001030329A2/en not_active Ceased
- 2000-10-27 ES ES00971593T patent/ES2225245T3/es not_active Expired - Lifetime
- 2000-10-27 JP JP2001532749A patent/JP2003512421A/ja active Pending
- 2000-10-27 AT AT00971593T patent/ATE273012T1/de not_active IP Right Cessation
- 2000-10-27 AU AU10427/01A patent/AU1042701A/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2005065069A3 (en) | Pharmaceutical methods, dosing regimes and dosage forms for the treatment of alzheimer's disease | |
| ES2374117T3 (es) | Componente de silibinina para el tratamiento de la hepatitis. | |
| JP2002528502A5 (enExample) | ||
| CA2066403A1 (en) | Transmucosal dosage form | |
| JP2004509061A5 (enExample) | ||
| EP0844878A1 (en) | 1,3-oxathiolane nucleoside analogues in the treatment of hepatitis c | |
| CA2467490A1 (en) | Pharmaceutical compositions of 5,8,14-triazatetracyclo[10.3.1.0(2,11).0(4,9)]-hexadeca-2(11)3,5,7,9-pentaene | |
| JP2005515966A5 (enExample) | ||
| PL363313A1 (en) | Deuterated 3-piperidinopropiophenone and medicaments containing said compounds | |
| WO2006017505A3 (en) | Pharmaceutical formulations comprising pleconaril for the treatment of airway diseases | |
| WO2002024203A3 (en) | Controlled release formulations for oral administration | |
| JP2005508963A5 (enExample) | ||
| EP1393734A4 (en) | DRUGS FOR INTESTINAL DISEASES | |
| JP2009517411A5 (enExample) | ||
| JP2002523437A5 (enExample) | ||
| JP2003512421A5 (enExample) | ||
| JP2002540148A5 (enExample) | ||
| JP2002326936A5 (enExample) | ||
| CA2474430A1 (en) | A combination of a thrombolytic agent and levosimendan for the treatment of acute myocardial infarction | |
| AR030551A1 (es) | Uso de nefiracetam para la fabricacion de un medicamento para eltratamiento de la neurodegeneracion y composicion farmaceutica resultante | |
| RU2003106417A (ru) | Применение комбинации витаминов для лечения первичных головных болей | |
| JP2008520672A (ja) | チプラナビルとダルナビルの共投与によるｈｉｖ感染症の治療方法 | |
| WO2004002498A1 (en) | Antiviral regimens | |
| WO2005020968A3 (en) | Use of oxcarbazepine for the treatment of diabetic neuropathic pain and the improvement of sleep | |
| JP2005145941A5 (enExample) |